Compounds > k 7174
Page last updated: 2024-12-11

k 7174

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

K 7174: inhibits binding of monocytes to cytokine-stimulated endothelial cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9874191
MeSH IDM0365565

Synonyms (23)

Synonym
1,4-bis[(e)-5-(3,4,5-trimethoxyphenyl)pent-4-enyl]-1,4-diazepane
1,4-bis[(4e)-5-(3,4,5-trimethoxyphenyl)pent-4-en-1-yl]-1,4-diazepane
286441-08-5
1h-1,4-diazepine, hexahydro-1,4-bis(5-(3,4,5-trimethoxyphenyl)-4-pentenyl)-, (e,e)-
1h-1,4-diazepine, hexahydro-1,4-bis((4e)-5-(3,4,5-trimethoxyphenyl)-4-pentenyl)-
1h-1,4-diazepine, hexahydro-1,4-bis((4e)-5-(3,4,5-trimethoxyphenyl)-4-penten-1-yl)-
36376CA57N ,
k 7174
k-7174 ,
191089-59-5
unii-36376ca57n
1,4-bis((e)-5-(3,4,5-trimethoxyphenyl)pent-4-en-1-yl)-1,4-diazepane
CS-3936
HY-12743
AKOS025404941
191089-60-8
BCP24218
k 7174; k-7174; k-7174(free base)
1h-1,4-diazepine, hexahydro-1,4-bis[(4e)-5-(3,4,5-trimethoxyphenyl)-4-penten-1-yl]-
Q27256515
1,4-bis[5-(3,4,5-trimethoxyphenyl)pent-4-en-1-yl]-1,4-diazepane
EN300-184399
EN300-23285788
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.01 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index17.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		3.4711diazine;
pyrazines		Daphnia magna metabolite
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		2.0110amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
bortezomib
[no description available]		3.4711amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ginsenoside m1
ginsenoside M1: structure in first source. ginsenoside C-K : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.		2.61012beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid		anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
hepatoprotective agent;
plant metabolite
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		2.4220
ConditionIndicatedRelationship StrengthStudiesTrials
Central Nervous System Lupus
[description not available]		03.5240
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		03.5240
Kahler Disease
[description not available]		03.4711
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		03.4711
Chronic Illness
[description not available]		02.0810
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		02.4420
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0810
Hematoma
A collection of blood outside the BLOOD VESSELS. Hematoma can be localized in an organ, space, or tissue.		02.0810
Hepatocellular Carcinoma
[description not available]		02.0210
Cancer of Liver
[description not available]		02.0210
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0210
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0210